

The first and only FDA-approved,
once-weekly treatment for use
in children with achondroplasia¹

Get your patients started with YUWIWEL

What to know about dosing & administration,
patient support enrollment, and more.

YUWIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.¹

This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).¹

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Low Blood Pressure

Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUWIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUWIWEL.

Please see Important Safety Information on p. 10 and 11 and the full [Prescribing Information](#) for YUWIWEL.

Get to know YUVIWEL

Flexible administration¹



YUVIWEL is the first and only once-weekly treatment allowing for 313 injection-free days per year¹



YUVIWEL leverages innovative TransCon[®] technology to provide continuous CNP exposure during the dosing interval, **counteracting the constitutively active FGFR3 in achondroplasia¹⁻³**



YUVIWEL was evaluated in a randomized, double-blind, placebo-controlled trial in children aged 2 to 12 years (N=84)¹

■ Primary efficacy endpoint¹


Annualized growth velocity (AGV) at Week 52

■ Secondary efficacy endpoint¹

Change from baseline in height Z-score at Week 52

In clinical trials, YUVIWEL was generally well tolerated¹

CNP=C-type natriuretic peptide; FGFR3=fibroblast growth factor receptor 3.



Please see Important Safety Information on p. 10 and 11 and the full [Prescribing Information](#) for YUVIWEL.



Administer at any time of day with or without food or drink
No need to plan administration around meals or snacks¹



Adjustable to help avoid missed doses
YUVIWEL offers the option to administer treatment up to 2 days before or after the scheduled dosing day^{1*}



YUVIWEL is a single once-weekly injection for children weighing <56 kg¹
For children ≥56 kg, 2 separate Kits are needed. The 2 injections should be given one after the other, using different injection sites¹

*If a dose of YUVIWEL is missed, administer the missed dose as soon as possible but not more than 2 days after the missed dosing day. Resume once-weekly dosing for the next dose at the previously scheduled dosing day. If more than 2 days have passed from the dosing day, skip the missed dose and administer the dose on the next regularly scheduled day. At least 5 days should elapse between doses.¹



Scan QR code to download full Instructions for Use. Learn how to reconstitute and administer YUVIWEL and more.

Caregivers should receive appropriate training by a healthcare provider prior to use. Refer them to the Instructions for Use for complete directions.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (≥5%) are vomiting, injection site reaction, pain in extremity, and nausea.

Weight-based dosing¹

How to switch to and store YUVIWEL

YUVIWEL dosing is based on body weight and administered by subcutaneous injection¹

Patient body weight, kg	Weekly dose, mg	Injection volume, mL	Vial strength for reconstitution, mg
8 - 9.9	0.88	0.4	1.3
10 - 13.4	1.2	0.55	
13.5 - 17.5	1.6	0.35	2.8
17.6 - 23	2.1	0.45	
23.1 - 30.5	2.8	0.6	
30.6 - 41.2	3.6	0.65	5.5
41.3 - 55.9	5	0.9	
56 - 73.5	6.6	1.2 mL (use 2 Kits) Administer 0.6 mL from each Kit	
73.6 - 90	8.8	1.6 mL (use 2 Kits) Administer 0.8 mL from each Kit	



Switch without missing a treatment day

- Instruct parents to give daily CNP analog as prescribed
- They can administer the first dose of YUVIWEL instead of CNP analog on the day after completing the last dose of daily CNP therapy¹




Easy to store

- Packaged in a small, single box for monthly use¹
- Store unreconstituted in the refrigerator or at room temperature^{1*†‡}

It is important to monitor weight and adjust dosage periodically.

Upon confirmation that no further growth is expected as indicated by closure of the epiphyses, discontinue use of YUVIWEL¹

*Store YUVIWEL refrigerated between 2 °C to 8 °C (36 °F to 46 °F). Store in the original packaging until time of use to protect from light. Do not freeze.¹
[†]Do not use YUVIWEL beyond the expiration date or 6 months after the date it was first removed from refrigeration (whichever is earlier).¹
[‡]Reconstituted YUVIWEL can be stored at room temperature up to 30 °C (86 °F) for up to 4 hours. Discard the unused reconstituted solution.¹
 CNP=C-type natriuretic peptide.



Please see Important Safety Information on p. 10 and 11 and the full Prescribing Information for YUVIWEL.

The Ascendis Signature Access Program® (A·S·A·P)*

Dedicated support resources for patients & providers

A·S·A·P is a team of specialists who coordinate with patients and providers throughout each stage of the access journey.



Enrolling in A·S·A·P is a simple 2-step process:

- 1. Enrollment Form**, filled out in-office and sent to A·S·A·P
- 2. Patient Consent Form**, filled out by patient

Personalized support every step of the way:

Benefits Investigations
Compiling a summary of benefits, sent to patient & office

Product Delivery
Coordination between specialty pharmacy & patient to ensure timely delivery

Prior Authorization Support
Coordination with insurance to navigate any prior authorization hurdles

Coordination of Financial Assistance for Eligible Patients†
Financial assistance for eligible patients is available, and can be arranged by the team


Injection Training Support for Patients
Dedicated training to ensure patients understand all steps for preparation & administration

*The A·S·A·P program provides patient support services to eligible patients who were provided an Ascendis medication for its approved indication. Patients are not eligible if they participate in any federal or state healthcare program.

†Terms and conditions apply. See [Eligibility and Restrictions](#).



YUWIWEL is available and distributed only through our single specialty pharmacy partner, Anovo.



Please see Important Safety Information on p. 10 and 11 and the full [Prescribing Information](#) for YUWIWEL.

Get to know the specialists:

Patient Access Liaison (PAL)

Ensures a seamless experience for the patient and their families by providing clinical education, offering injection training support, and walking them through the insurance process.

Field Reimbursement Manager (FRM)

Provides helpful information to healthcare professionals and staff to help support completion of enrollment forms, clarifies prior authorization or medical exception requirements, and advises on appeals.



Scan the QR code to view the **Patient Enrollment Form and Patient Consent Form**. Both forms can be submitted by fax to 1-888-436-0193. For any questions, please call **1-844-442-7236** and select **option 3**.

Questions you may hear regarding YUVIWEL

Q&A

Q How do I prepare and administer YUVIWEL?

A YUVIWEL must be reconstituted and carefully prepared according to the Instructions for Use. The Instructions for Use video can show you and your patients how to use it, step-by-step. It may be helpful to watch the video with parents and answer any additional questions they may have. The video can be found at [YuviwelHCP.com/dosing-and-administration/#instructions-for-use](https://yuviwelhcp.com/dosing-and-administration/#instructions-for-use).¹

Q Can parents/caregivers get help learning how to prepare and administer YUVIWEL?

A Caregivers should receive appropriate training by a healthcare provider prior to use. A-S-A-P provides access to a team of specialists who can offer families at-home training to help.

Q Are savings programs available?

A Savings programs are available for patients who meet specific eligibility requirements. Direct them to yuviwel.com/support-services for more information, or they can call 1-844-442-7236 and select option 3.

Q&A

Q How do I sign my patient up for A-S-A-P?

A Your office fills out a Patient Enrollment Form, the patient fills out a Patient Consent Form, and then the A-S-A-P process begins.

Q Does YUVIWEL have a dedicated specialty pharmacy?

A Yes. YUVIWEL is available and distributed only through the specialty pharmacy Anovo. Field Reimbursement Managers can help your office coordinate with Anovo, and Patient Access Liaisons can help patients understand the process.


Q How is YUVIWEL stored?

A YUVIWEL offers flexible storage and can be stored unreconstituted in the refrigerator or at room temperature.¹

For other questions, please reach out to an Ascendis representative



YUVIWEL (YOU-vih-well)
navepegritide (nav-uh-PEG-rih-tide)



Please see Important Safety Information on p. 10 and 11 and the full [Prescribing Information](#) for YUVIWEL.

Important Safety Information

INDICATION AND USAGE

YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.

This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION


WARNINGS AND PRECAUTIONS

Risk of Low Blood Pressure

Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.

ADVERSE REACTIONS

The most common adverse reactions ($\geq 5\%$) are vomiting, injection site reaction, pain in extremity, and nausea.



Important Safety Information (cont'd)

SPECIFIC POPULATIONS

Pregnancy and Lactation

There are no available data on the use of YUVIWEL in pregnant women, or data on the presence of YUVIWEL in human milk, the potential effects on milk production or the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for YUVIWEL and any potential adverse effects on the breastfed infant from YUVIWEL or from the underlying maternal condition.

Renal Impairment

YUVIWEL is not recommended for patients with moderate or severe renal impairment.

You are encouraged to report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.


Please see full [Prescribing Information](#) for YUVIWEL.

References: 1. YUVIWEL. Prescribing information. Ascendis Pharma, Inc.; 2026. 2. Breinholt VM, Rasmussen CE, Mygind PH, et al. TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias. *J Pharmacol Exp Ther.* 2019;370(3):459-471. 3. Horton WA, Hall JG, Hecht JT. Achondroplasia. *Lancet.* 2007;370(9582):162-172.

The first and only FDA-approved, once-weekly treatment for use in children with achondroplasia¹



313 injection-free days
per year¹



**Administer at any
time of day**, with or
without food or drink¹



**Dedicated support
is available** through the
Ascendis Signature
Access Program (A-S-A-P)

Visit [YuviwelHCP.com](https://yuviwelhcp.com) to register for periodic updates regarding YUWIWEL

INDICATION AND USAGE

YUWIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.

This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Low Blood Pressure

Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUWIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUWIWEL.

Please see Important Safety Information on p. 10 and 11 and the full [Prescribing Information](#) for YUWIWEL.